BFEC
ATRS

Benjamin F. Edwards & Company’s Antares Pharma, Inc. ATRS Stock Holding History

Benjamin F. Edwards & Company’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6,000
Closed -$19K – 1603
2017
Q2 		$19K Buy
+6,000
New +$17K ﹤0.01% 921

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Benjamin F. Edwards & Company's ATRS Position: Q3 2017 in Review

Benjamin F. Edwards & Company sold out of Antares Pharma, Inc. (ATRS) in Q3 2017, closing a stake of 6,000 shares — an estimated $19K sold.

Benjamin F. Edwards & Company first reported a position in ATRS in Q2 2017 and held it in 1 quarter. The position peaked at $19K in Q2 2017. 103 funds tracked by Wall St. Rank hold ATRS as of Q3 2017.

  • Benjamin F. Edwards & Company reported no remaining Antares Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 6,000 Antares Pharma, Inc. shares in Q3 2017, an estimated $19K.
  • Benjamin F. Edwards & Company first reported a position in Antares Pharma, Inc. in Q2 2017 and held it in 1 quarter.
  • Benjamin F. Edwards & Company's Antares Pharma, Inc. position peaked at $19K in Q2 2017.
  • 103 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2017.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2017, filed 24 Oct 2017.